Pfizer, Inc.
PFE · NYSE
- $27.72
- $158.05B
- Open
- —
- —
- $27.69 - $28.19
- $23.58 - $29.21
- —
- —
- 28.50M
About Pfizer, Inc.
Pfizer is a global drug major that develops and sells prescription medicines and vaccines to patients through healthcare providers, pharmacies, hospitals and other healthcare systems. Its portfolio includes COVID products, alongside other pharmaceutical products, although the supplied evidence does not provide a segment breakdown or quantify how much each business contributes. Pfizer generated $62.6 billion of revenue and $7.8 billion of net income in FY2025, compared with $63.6 billion and $8.0 billion, respectively, in FY2024. Its current scale is therefore roughly $63 billion in annual revenue, with COVID products remaining a specifically identified business line.
Notable Price Movement
- Aug 3-7$26.767.00%
Pfizer rose $0.16, or 0.63%, from $25.25 to $25.41 over the week. The stock initially weakened from $25.25 on July 28 to $24.91 on July 30, then recovered modestly to $25.03 on August 3. The decisive move came on August 4, when shares gained $0.38, or roughly 1.5%, on second-quarter results that exceeded earnings and revenue estimates by 13.24% and 4.04%, respectively. Pfizer also raised the low end of its 2026 sales outlook and maintained its earnings view, although it lowered expected COVID-product revenue. The quarterly loss caused by one-time charges likely limited enthusiasm, but the supplied evidence points primarily to earnings and guidance rather than broader market factors.
